Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 4—April 2019
Dispatch

Aerosol Transmission of Aspergillus fumigatus in Cystic Fibrosis Patients in the Netherlands

Figures
Tables
Article Metrics
30
citations of this article
EID Journal Metrics on Scopus
Author affiliations: Radboud University Medical Center, Nijmegen, the Netherlands (T.G.P. Engel, E. Erren, K.S.J. Vanden Driessche, W.J.G. Melchers, M.H. Reijers, P. Merkus, P.E. Verweij); Center of Expertise in Mycology Radboud UMC/CWZ, Nijmegen (T.G.P. Engel, W.J.G. Melchers, M.H. Reijers, P.E. Verweij)

Cite This Article

Abstract

We collected sputum samples and cough plates from 15 cystic fibrosis patients in the Netherlands who were colonized with Aspergillus fumigatus; we recovered A. fumigatus of the same genotype in cough aerosols and sputum samples from 2 patients. The belief that transmission of A. fumigatus from cystic fibrosis patients does not occur should be reconsidered.

Progressive lung injury in cystic fibrosis (CF) patients can lead to chronic colonization with bacteria and fungi (1,2). Different routes of patient-to-patient transmission have been identified for various microorganisms (3). For saprophytic molds, such as Aspergillus fumigatus, exposure to aerosolized conidia in the environment is believed to be the primary route leading to colonization of the airways (3). Secretion of these fungi from the human lung into the environment is thought not to occur, and the general view is that humans are dead-end hosts of filamentous fungi. However, some reports have provided information suggesting that this belief might need to be revised (4). We set out to examine whether aerosol formation of A. fumigatus occurs in CF patients during coughing.

The Study

During 2017–2018, we invited 15 adult CF patients in the Netherlands who were colonized with A. fumigatus to participate in a cough plate experiment. We defined A. fumigatus colonization as the recovery of A. fumigatus from >50% of sputum samples collected over the course of the 2 previous years. To enable genetic comparisons among study samples, we stored cultured fungal isolates from included patients in the Radboud University Medical Center Medical Microbiology Department (Nijmegen, the Netherlands) fungal species bank. We performed sample collection during 2 routine quarterly visits before or after routinely performed spirometry. We instructed participants to take a maximal inspiration and cough twice on each of 2 different agar plates, Sabouraud dextrose agar and Columbia blood agar, held at a 5-cm distance from the participant’s mouth. In addition, we collected a sputum sample on the same day or alternatively within a month if the participant was unable to produce sputum during the visit. We incubated Sabouraud dextrose agar cough plates at 28°C and Columbia blood agar cough plates at 36°C for 3 weeks and inspected daily for bacterial and fungal growth. We processed sputum samples according to CF guidelines (3). We collected individual CFUs (up to a maximum of 20 CFUs per sample) from cough plates and sputum cultures and genotyped A. fumigatus CFUs using microsatellite genotyping (5). We considered the detection of identical A. fumigatus genotypes from cough plates and sputum samples as proof of aerosolization of A. fumigatus from humans. We genotyped up to 6 sputum cultures of stored A. fumigatus isolates from each participant.

This study was reviewed by the institutional review board, which considered the study exempt from further institutional review board oversight in accordance with the law in the Netherlands on research with humans. All participants provided informed consent.

Figure

Thumbnail of Genotyping results of Aspergillus fumigatus isolates in sputum cultures and on cough plates obtained from 2 participants with cystic fibrosis demonstrating aerosol formation of A. fumigatus, the Netherlands, 2015–2018. For samples collected after August 2017, a maximum of 20 isolates per sputum culture were saved. For samples collected earlier, only 1 sputum sample isolate was saved. Genotypes of the isolates collected from patient 4 (A) and 15 (B) are indicated. The superscript num

Figure. Genotyping results of Aspergillus fumigatus isolates in sputum cultures and on cough plates obtained from 2 participants with cystic fibrosis demonstrating aerosol formation of A. fumigatus, the Netherlands, 2015–2018. For samples...

We cultured A. fumigatus from 18 (60%) sputum samples collected from 11 different participants (Table). A. fumigatus was also recovered from 3 (17%) of the 18 corresponding cough plate samples; these 3 samples were from 2 different participants. In both cases, cough plates had been acquired after the participant had undergone spirometry. Genotyping of the A. fumigatus isolates from sputum samples and cough plates from both participants showed identical genotypes. One participant was colonized with at least 10 different A. fumigatus genotypes (Figure). In this participant, the genotype recovered from the cough plate was not found in the sputum sample collected at the same visit but in the sputum sample recovered at the next visit. The second participant was colonized with a single genotype, which was recovered from multiple cough plates and sputum samples.

We also assessed for bacterial species present on cough plates and in sputum samples to enable comparison of transmission frequencies among pathogens. The cough secretion frequency for Pseudomonas aeruginosa was 67% (10/15) and for Staphylococcus aureus was 19% (3/16) (Table). No growth of Stenotrophomonas maltophilia on cough plates was observed.

Our study demonstrates that A. fumigatus can be recovered from cough aerosols from colonized CF patients with a similar frequency as S. aureus. This aerosolization is strikingly occurring in CF outpatients without any cavitary lesions or other serious complications. Cavitary lesions can facilitate sporulation of A. fumigatus inside patient lungs and thereby aids in fungal secretion.

By continuously monitoring indoor airborne fungal contamination with electrostatic dustfall collectors, Lemaire et al. identified patient airways as the source of A. fumigatus contamination in an intensive care unit (4). Microsatellite genotyping showed that the airborne A. fumigatus and isolates from the patient’s respiratory samples were identical. That observation and our study results indicate that the current consensus that transmission of A. fumigatus from colonized or infected patients does not occur should be reconsidered.

Although CF patients are typically colonized with unique A. fumigatus genotypes, several studies report the recovery of identical A. fumigatus genotypes from different CF patients (6). These genotypes could not be linked to a common environmental source and thus remained unexplained, but identical genotypes in different patients might point toward patient-to-patient transmission (6). Patient-derived azole resistance mutations have been reported in CF patient (7) and environmental (8) isolates. The mechanism for acquisition of azole resistance is unknown for environmental isolates, but resistance might have developed in isolates during human infection or colonization and then subsequently spread into the environment. Our observation of A. fumigatus in cough aerosols suggests droplet or airborne transmission as potential routes of patient-to-patient transmission. Traits such as azole resistance might spread through cough aerosols from patient to patient or from patient to environment. Both participants with positive cough plates had undergone spirometry before coughing, indicating that maximal inspiration and expiration might facilitate the release of A. fumigatus.

Aerosolized A. fumigatus conidia from environmental sources could represent a greater and more continuous burden for CF patients than potentially aerosolized conidia from patients. However, some studies suggest that A. fumigatus in chronically infected patients undergoes an evolutionary trajectory resulting in strains with specific traits that are better adapted to the lung environment (9,10). Endogenous and exogenous stress factors, such as host immunity or exposure to antifungal azoles, might result in the selection of traits that are better able to resist these stress factors (11). Isolates that are better adapted to the lung environment might have a greater propensity than environmental isolates to successfully colonize and persist in the airways of CF patients. In CF, 42% of azole resistance is derived through in-host selection and is thought to be associated with prolonged (prophylactic) use of anti-Aspergillus azoles (12,13). Passaging through the lungs of CF patients conceivably could provide A. fumigatus isolates the opportunity to acquire specific traits that increase their ability to survive in different environments. Evolution experiments have confirmed the potential of A. fumigatus to rapidly adapt to various environments (9).

Conclusions

In summary, our results show that A. fumigatus can be recovered from cough aerosols of colonized CF patients. These findings underscore the need for additional studies to further elaborate transmission dynamics of A. fumigatus, evaluate if patient-to-patient transmission occurs, and determine if additional infection prevention measures are required.

Mr. Engel is a resident in clinical microbiology and a doctoral candidate in the Radboud University Medical Center, Nijmegen, the Netherlands. His primary research interest is in mycology, especially fungal colonization in CF patients.

Top

References

  1. Elborn  JS. Cystic fibrosis. Lancet. 2016;388:251931. DOIPubMedGoogle Scholar
  2. Schwarz  C, Bouchara  JP, Buzina  W, Chrenkova  V, Dmeńska  H, de la Pedrosa  EGG, et al. Organization of patient management and fungal epidemiology in cystic fibrosis. Mycopathologia. 2018;183:719. DOIPubMedGoogle Scholar
  3. Saiman  L, Siegel  JD, LiPuma  JJ, Brown  RF, Bryson  EA, Chambers  MJ, et al.; Cystic Fibrous Foundation; Society for Healthcare Epidemiology of America. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol. 2014;35(Suppl 1):S167. DOIPubMedGoogle Scholar
  4. Lemaire  B, Normand  A-C, Forel  J-M, Cassir  N, Piarroux  R, Ranque  S. Hospitalized patient as source of Aspergillus fumigatus, 2015. Emerg Infect Dis. 2018;24:15247. DOIPubMedGoogle Scholar
  5. de Valk  HA, Meis  JF, Curfs  IM, Muehlethaler  K, Mouton  JW, Klaassen  CH. Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates. J Clin Microbiol. 2005;43:411220. DOIPubMedGoogle Scholar
  6. de Valk  HA, Klaassen  CHW, Yntema  JB, Hebestreit  A, Seidler  M, Haase  G, et al. Molecular typing and colonization patterns of Aspergillus fumigatus in patients with cystic fibrosis. J Cyst Fibros. 2009;8:1104. DOIPubMedGoogle Scholar
  7. Morio  F, Aubin  GG, Danner-Boucher  I, Haloun  A, Sacchetto  E, Garcia-Hermoso  D, et al. High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis. J Antimicrob Chemother. 2012;67:18703. DOIPubMedGoogle Scholar
  8. Bader  O, Tünnermann  J, Dudakova  A, Tangwattanachuleeporn  M, Weig  M, Groß  U. Environmental isolates of azole-resistant Aspergillus fumigatus in Germany. Antimicrob Agents Chemother. 2015;59:43569. DOIPubMedGoogle Scholar
  9. Verweij  PE, Zhang  J, Debets  AJM, Meis  JF, van de Veerdonk  FL, Schoustra  SE, et al. In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: a dilemma for clinical management. Lancet Infect Dis. 2016;16:e25160. DOIPubMedGoogle Scholar
  10. Ballard  E, Melchers  WJG, Zoll  J, Brown  AJP, Verweij  PE, Warris  A. In-host microevolution of Aspergillus fumigatus: A phenotypic and genotypic analysis. Fungal Genet Biol. 2018;113:113. DOIPubMedGoogle Scholar
  11. Zelante  T, Iannitti  RG, De Luca  A, Arroyo  J, Blanco  N, Servillo  G, et al. Sensing of mammalian IL-17A regulates fungal adaptation and virulence. Nat Commun. 2012;3:683. DOIPubMedGoogle Scholar
  12. Mortensen  KL, Jensen  RH, Johansen  HK, Skov  M, Pressler  T, Howard  SJ, et al. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance. J Clin Microbiol. 2011;49:224351. DOIPubMedGoogle Scholar
  13. Hamprecht  A, Morio  F, Bader  O, Le Pape  P, Steinmann  J, Dannaoui  E. Azole resistance in Aspergillus fumigatus in patients with cystic fibrosis: a matter of concern? Mycopathologia. 2018;183:15160. DOIPubMedGoogle Scholar

Top

Figure
Table

Top

Cite This Article

DOI: 10.3201/eid2504.181110

Original Publication Date: March 04, 2019

Table of Contents – Volume 25, Number 4—April 2019

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Tobias G.P. Engel, Radboud University Medical Center, Department of Medical Microbiology, Route 777, Geert Grooteplein Zuid 10, 6500 HB Nijmegen, the Netherlands

Send To

10000 character(s) remaining.

Top

Page created: March 18, 2019
Page updated: March 18, 2019
Page reviewed: March 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external